Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
Fate Therapeutics stock last closed at $1.27, down 9.29% from the previous day, and has decreased 77.16% in one year. It has underperformed other stocks in the Biotechnology industry by 0.46 percentage points. Fate Therapeutics stock is currently +22.12% from its 52-week low of $1.04, and -85.62% from its 52-week high of $8.83.
As of Feb 7, 2025, there are 113.89M shares of FATE outstanding. The market value of FATE is $144.65M. In the past 24 hours, 1.01M FATE shares were traded.
How to Buy Fate Therapeutics Stock
Wondering how to invest in Fate Therapeutics stock? Here's how.
Decide where to buy Fate Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you choose where to buy Fate Therapeutics stock.
Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
Deposit funds into your investment account: Pick your method of payment and add your information.
Evaluate Fate Therapeutics stock: The Fate Therapeutics ticker symbol is FATE. Is Fate Therapeutics stock a good investment? Should you buy shares of FATE? How do FATE's underlying business fundamentals look? Do top analysts think Fate Therapeutics is a good buy? Why has FATE's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if FATE is a good stock to buy).
Execute your FATE trade: Decide if you will purchase FATE shares at the current market price or use a limit order to purchase FATE stock at a particular price.
Get the latest scoop on your investment in FATE: Create a watchlist to get live updates on your position in Fate Therapeutics shares.
Step 1: Decide where to buy Fate Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy FATE stock.
A brokerage account enables you to buy and sell a variety of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
Based on our experience, eToro is the best online stock brokerage. Here's why:
You can invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
Access to global markets: From Tech to Real Estate, New York to Shanghai — you can fill your portfolio with stocks from the world's leading exchanges.
Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by creating an account with eToro today.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create your brokerage account
Now that you've selected the best brokerage, you'll need to fill out some personal information so you can buy FATE stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Fate Therapeutics stock
After you have chosen the best place to buy Fate Therapeutics stock, it's absolutely critical to analyze their stock prior to buying, so you can comprehend the risk and opportunity.
Fate Therapeutics Numbers
FATE Price
$1.27
1w %
-2.31%
1y %
-77.16%
5y %
-95.09%
P/E
-0.77x
P/B
0.4x
P/S
11.14x
PEG
N/A
Revenue
$13.45M
Earnings
-$178.23M
Fore. Rev. Growth
124.19%
Fore. Earn. Growth
N/A
Market Cap
$144.65M
Next Earnings
Feb 24, 2025
Next Dividend
N/A
FATE Fundamentals
WallStreetZen was created to help part-time investors do better fundamental analysis quickly.
Last year, FATE revenue was $13.45M. During the past five year, FATE's revenue has gone up by 7.11% per year. This was slower than the Biotechnology industry average of 58.54%.
In the last year, executives and large shareholders at FATE have bought more shares than they have sold.
Jerome Charles Bressi, Chief Regulatory and Quality Officer of FATE, was the latest FATE insider to sell. They sold $9,269.00 worth of FATE shares on Jan 10, 2025.
No, Fate Therapeutics doesn't provide an income stream by paying out dividends.
What do other investors have to say about FATE?
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your FATE trade
You have two primary types of orders:
Market order: A market order is an order to buy or sell a security at the best available price. Market orders are generally the best for newer investors.
Limit order: A limit order enables you to buy or sell a security at a specific price (or better). If you want to make sure you're buying or selling at a given price limit, use a limit order.
Press the Open Trade button and your broker will execute your order.
If you require additional assistance investing in stocks on eToro, click the helpful video below:
How much does it cost to buy one Fate Therapeutics share?
As of Feb 7, 2025, it costs $1.27 to buy one share of Fate Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $0.64, you can buy 0.5 shares of FATE.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.